What next for preimplantation genetic screening? High mitotic chromosome instability rate provides the biological basis for the low success rate by Vanneste, Evelyne et al.
DEBATE
What next for preimplantation genetic
screening? High mitotic chromosome
instability rate provides the biological
basis for the low success rate
Evelyne Vanneste1,2,†, Thierry Voet1,†, Cindy Melotte1,
Sophie Debrock2, Karen Sermon3, Catherine Staessen3,
Inge Liebaers3, Jean-Pierre Fryns1, Thomas D’Hooghe2,
and Joris R. Vermeesch1,4
1Center for Human Genetics, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium
2Leuven University Fertility
Center, University Hospital Gasthuisberg, Leuven, Belgium
3Center for Medical Genetics, University Hospital and Medical School, Dutch-
speaking Brussels Free University, Brussels, Belgium
4Correspondence address. Center for Human Genetics, University Hospital Gasthuisberg, Herestraat 49, Box 602, 3000 Leuven, Belgium.
E-mail: joris.vermeesch@uz.kuleuven.be
Preimplantation genetic screening is being scrutinized, as recent randomized clinical trials failed to observe the expected signiﬁcant increase in
live birth rates following ﬂuorescence in situ hybridization (FISH)-based screening. Although these randomized clinical trials are criticized on
their design, skills or premature stop, it is generally believed that well-designed and well-executed randomized clinical trials would resolve the
debate about the potential beneﬁt of preimplantation genetic screening. Since FISH can analyze only a limited number of chromosomal loci,
some of the embryos transferred might be diagnosed as ‘normal’ but in fact be aneuploid for one or more chromosomes not tested. Hence,
genome-wide array comparative genome hybridization screening enabling aneuploidy detection of all chromosomes was thought to be a ﬁrst
step toward a better design. We recently showed array screening indeed enables accurate determination of the copy number state of all
chromosomes in a single cell. Surprisingly, however, this genome-wide array screening revealed a much higher frequency and complexity
of chromosomal aberrations in early embryos than anticipated, with imbalances in a staggering 90% of all embryos. The mitotic error
rate in cleavage stage embryos was proven to be higher than the meiotic aneuploidy rate and as a consequence, the genome of a single
blastomere is not representative for the genome of the other cells of the embryo. Hence, potentially viable embryos will be discarded
upon screening a single blastomere. This observation provides a biological basis for the failure of the randomized clinical trials to increase
baby-take-home rates using FISH on cleavage stage embroys.
Preimplantation genetic screening (PGS), also termed preimplantation
genetic diagnosis with aneuploidy screening or PGD-AS, is increasingly
implemented in fertility centers worldwide (Harper et al., 2008). The
decreasing fecundity of older women caused by age-dependent
oocytic and embryonic aneuploidy, and the knowledge that the
majority of chromosomal errors cause embryonic lethality led to the
hypothesis that selection of chromosomally normal embryos for
uterine transfer would increase the live birth rate and decrease the
spontaneous miscarriage rate per embryo transferred (Verlinsky
et al., 1995). In PGS, one or two blastomeres from a cleavage stage
embryo are biopsied for genetic analysis. Routinely, 7 up to 12 chro-
mosomal loci are scored using multi-probe ﬂuorescence in situ hybrid-
ization (FISH). In addition to advanced maternal age, recurrent
implantation failure, sporadic or recurrent miscarriages as well as
factors of severe male infertility have been added to the list of indi-
cations for PGS (Harper et al., 2008). Some groups even propose
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embryos (Verlinsky et al., 2005).
Despite the attractiveness of the scientiﬁc and clinical rationale
for PGS and promising results from studies with matched controls
(Gianaroli et al., 1999; Munne et al., 2003), recent randomized pro-
spective clinical trials failed to observe a signiﬁcantly increased live
birth rate after transfer of chromosomally ‘normal’ embryos selected
by FISH following PGS (Staessen et al., 2004, 2008; Mastenbroek et al.,
2007; Hardarson et al., 2008; Schoolcraft et al., 2008; Twisk et al.,
2006, 2008; Debrock et al., 2009). These results, at odds with the
expected outcome based upon the scientiﬁc rationale for PGS, trig-
gered a ﬁerce debate about the usefulness of PGS in clinical practice
(Goldman, 2007; Fauser, 2008; Harper et al., 2008; Mastenbroek
et al., 2008; Simpson, 2008). According to proponents, FISH-based
PGS improves IVF outcome on the condition that a speciﬁc set of
chromosomes is screened in only one blastomere biopsied by an
experienced embryologist. Consequently, PGS using full genomic
screening for chromosomal imbalances is expected to further
improve the outcome of PGS. According to PGS skeptics, FISH-based
PGS is not efﬁcient in selecting the best embryo and whole genome
analysis of one blastomere might be superior to FISH-based PGS. A
second concern is that the presence of chromosomal mosaicism
might hamper its success.
We developed a novel array-based approach to reliably screen
genome-wide chromosomal imbalances with a high resolution in a
single cell and analyzed every blastomere from 23 good-quality clea-
vage stage embryos (2–5 blastomeres on day 2, 6–10 blastomeres
on day 3, ,20% fragmentation, equal-sized blastomeres). These
embryos were derived from nine fertile young couples (female age
,35 years; normal karyotype of both partners; a maternal body
mass index of 18–30 kg/m
2; initial normal semen parameters accord-
ing to WHO regulations; no history of recurrent miscarriages) treated
with ART and PGD for sex selection due to X-linked disorders and a
BRCA mutation or for familial microdeletion syndromes. The mean
Figure 1 The karyogram of embryo 19 is shown. The karyogram is composed of color bars that each represent the chromosome copy number
state based on the results of the BAC (bacterial artiﬁcial chromosomes) array and the SNP (single nucleotide polymorphism) copy number and geno-
typing data in a speciﬁc blastomere. Black represents a normal region, red a hemizygous deletion, green a duplication, dark green an ampliﬁcation and
gray discordance between the analyses or unreliable aberrations. In this male embryo, whole chromosome imbalances of mitotic origin were detected
in chromosomes 1 and 14, whereas chromosome 20 showed a monosomy in all sister blastomeres suggesting a meiotic non-disjunction. Moreover, 4q
and 10q terminal deletions with a reciprocal 4q duplication and 10q ampliﬁcation respectively were detected in a proportion of its sister blastomeres.
Finally, a 5q terminal deletion and reciprocal 5q duplication were detected in two blastomeres, whereas the remaining part of the chromosome prox-
imal to the 5q deletion was trisomic. Two sister blastomeres contained a monosomy for chromosome 5. In addition, a remaining sister blastomere
contained three copies of chromosome 5, whereas a ﬁfth lacked a 5q terminal part of which the size was equal to the partial deletion and duplication in
its sister blastomeres.
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per cycle (13 cycles for nine patients) of which 29% were FISH-
diagnosed to be suitable for transfer (least affected sex or non-
microdeletion carrier). We used all remaining blastomeres of the
fresh and biopsied 3- and 4-day-old good-quality embryos carrying a
microdeletion or a sex-selected against. This set-up allowed us to
identify accurately the frequency of chromosomal and segmental
imbalances and to analyze the meiotic versus mitotic origin of each
aberration in embryos that are the best available representation of
normal human embryogenesis. Stringent interpretation criteria and
exclusion due to quality control (34% of the blastomeres) ensured
that the number of chromosomal imbalances represents a lower esti-
mate. Surprisingly, a staggering 21 embryos showed chromosomal
mosaicism and only 2 embryos were normal diploid in all blastomeres.
In the abnormal embryos, not only mosaicism for whole chromosome
aneuploidies (83% of the embryos) and uniparental disomies (9%
of the embryos) were detected, but also frequent terminal segmental
deletions, duplications or ampliﬁcations (70% of the embryos), these
being often recurrent or reciprocal in the sister blastomeres of an
embryo (Figure 1) (Vanneste et al., 2009). Although this aneuploidy
rate in embryos from normal fertile young women might seem exces-
sively high, 48% of the embryos do contain normal diploid blastomeres
as well (Vanneste et al., 2009). Moreover, when the genome-wide
screening data are extrapolated to the data obtained on human
embryos by screening a limited number of chromosomal loci by
FISH, the degrees of aneuploidy obtained by both techniques are
similar (Vanneste et al., 2009). Finally, complex chromosomal abnorm-
alities that have been reported from the investigation of fetal tissue
after spontaneous miscarriages have now been detected in human
embryos as well (Vanneste et al., 2009).
These data provide the molecular basis for the failure of random-
ized controlled PGS trials in improving the baby-take-home rate.
First, rather than being conﬁned to groups at risk of a low pregnancy
success rate following IVF/ICSI, our study shows that chromosome
instability (i.e. the gain or loss of complete chromosomes or segments
of chromosomes, resulting in cell-to-cell variability) is common to all
human embryos (post-IVF/ICSI). Although the meiotic aneuploidy
rate is known to increase with age (Wilton, 2002), this mitotic
chromosome instability rate of 91% is higher than any meiotic aneu-
ploidy rate. Therefore, there is no argument to target cleavage stage
PGS treatment to speciﬁc patients with low pregnancy success rates
following IVF/ICSI. Second, PGS assumes that one or two blastomeres
are representative of the chromosome status of the remaining blasto-
meres of the embryo (Wilton, 2002). The astonishingly high degree of
chromosomal mosaicism in cleavage stage embryos undermines this
assumption. Third, the high frequency of potentially detrimental seg-
mental chromosomal aberrations (70% of the embryos) shows
that locus-speciﬁc FISH screening can only detect a minor fraction
of all chromosomal imbalances. Consequently, all studies that use
FISH screening have a serious bias toward diagnosing genetically
‘normal’ embryos for transfer. Genome-wide screening would
increase the accuracy of the genetic diagnosis but would signiﬁcantly
reduce the number of embryos suitable for transfer. Finally, the
,10% fully normal diploid cleavage stage embryos is less than the
pregnancy success rate following IVF/ICSI with PGD in our as well
as other centers (ESHRE PGD consortium Goossens et al., 2008;
Vanneste et al., 2009). This adds another argument to the concept
that at least some uterine-transferred mosaic diploid/aneuploid
embryos can survive to term in a healthy state, suggesting that chro-
mosomally normal blastomeres grow preferentially to abnormal cells
during early embryogenesis before, during and after embryo implan-
tation. Determining the genetic content of human embryos based
on the analysis of one or two cells before self-correction and/or self-
selection has occurred, most often at day 3 after fertilization, will thus
inevitably result in discarding potentially viable embryos.
In conclusion, the prevalent chromosome instability in all early
human cleavage stage embryos (post-IVF/ICSI) provides a biological
basis for the failure of cleavage stage PGS in improving the live birth
rate per embryo transferred. Although, in general, the ﬁeld assumes
that genome-wide cleavage stage aneuploidy screening is the way
ahead, our new data demonstrate that other strategies will be
required. Understanding the mechanisms underlying this chromosome
instability in embryos, which is reminiscent of the chromosome
instability observed during tumorigenesis, will be a ﬁrst step toward
this aim.
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